Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 8
Submit an article Journal homepage
1,166
Views
26
CrossRef citations to date
0
Altmetric
Author's View

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer

Magali Terme INSERM U970; PARCC (Paris Cardiovascular Research Center); Université Paris-Descartes; Sorbonne Paris Cité; Paris, FranceCorrespondence[email protected] [email protected]
,
Eric Tartour INSERM U970; PARCC (Paris Cardiovascular Research Center); Université Paris-Descartes; Sorbonne Paris Cité; Paris, France; Service d’Immunologie Biologique Hôpital Européen Georges Pompidou; Assistance Publique-Hôpitaux de Paris; Paris, France
&
Julien Taieb INSERM U970; PARCC (Paris Cardiovascular Research Center); Université Paris-Descartes; Sorbonne Paris Cité; Paris, France; Service d’Hépatogastroentérologie et d’Oncologie Digestive; Hôpital Européen Georges Pompidou; Assistance Publique-Hôpitaux de Paris; Paris, FranceCorrespondence[email protected] [email protected]
Article: e25156 | Received 21 May 2013, Accepted 23 May 2013, Published online: 10 Jun 2013

Figures & data

Figure 1. Impact of VEGFA/VEGFR-targeted therapeutics on tumor-induced immunosuppression. Tumor-derived vascular endothelial growth factor A (VEGFA) can block the maturation of dendritic cells (DCs) and induce the expansion of myeloid-derived suppressor cells. Immature DCs as well as MDSCs favor the generation of regulatory T cells (Tregs). VEGFA can also induce the proliferation of VEGF receptor 2 (VEGFR2)+ Tregs. VEGFA/VEGFR-targeted therapies can exert antineoplastic effects by interfering with all these mechanisms.

Figure 1. Impact of VEGFA/VEGFR-targeted therapeutics on tumor-induced immunosuppression. Tumor-derived vascular endothelial growth factor A (VEGFA) can block the maturation of dendritic cells (DCs) and induce the expansion of myeloid-derived suppressor cells. Immature DCs as well as MDSCs favor the generation of regulatory T cells (Tregs). VEGFA can also induce the proliferation of VEGF receptor 2 (VEGFR2)+ Tregs. VEGFA/VEGFR-targeted therapies can exert antineoplastic effects by interfering with all these mechanisms.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.